Anti-galectin-3 therapy: A new chance for multiple myeloma and ovarian cancer?

Leonardo Mirandola, Diane D. Nguyen, Rakhshanda L. Rahman, Fabio Grizzi, Yu Yuefei, José A. Figueroa, Marjorie R. Jenkins, Everardo Cobos, Maurizio Chiriva-Internati

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

Here we review the role of Galectins in the molecular pathogenesis of multiple myeloma and ovarian cancer, with a special focus on Glectin-3. Multiple myeloma is the second most common hematologic malignancy worldwide. Because the pathogenesis of multiple myeloma is still incompletely understood, there is no ultimately effective cure, and this cancer results fatal. Ovarian cancer is the most lethal gynecologic malignancy worldwide. Due to the lack of screening techniques for early detection, patients are mostly diagnosed with advanced disease, which results ultimately fatal. Multiple myeloma and ovarian cancer have different biologies, but they share a strong dependence on adhesion with extracellular matrix and other cells. Galectin-3 plays a key role in regulating such adhesive abilities of tumor cells. Here we discuss the outcomes and possible mechanism of action of a truncated, dominant negative form of Galectin-3, Galectin-3C, in these malignancies. Overall, we report that Galectin-3C is a promising new compound for effective adjuvant therapies in advanced, refractory multiple myeloma and ovarian cancer.

Original languageEnglish (US)
Pages (from-to)417-427
Number of pages11
JournalInternational Reviews of Immunology
Volume33
Issue number5
DOIs
StatePublished - Sep 3 2014

    Fingerprint

Keywords

  • Adhesion
  • Drug resistance
  • Galectins
  • Multiple myeloma
  • NF-κB
  • Ovarian cancer

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Mirandola, L., Nguyen, D. D., Rahman, R. L., Grizzi, F., Yuefei, Y., Figueroa, J. A., Jenkins, M. R., Cobos, E., & Chiriva-Internati, M. (2014). Anti-galectin-3 therapy: A new chance for multiple myeloma and ovarian cancer? International Reviews of Immunology, 33(5), 417-427. https://doi.org/10.3109/08830185.2014.911855